TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Restylane Lyft Lidocaine for Jawline Definition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults willing to comply with the requirements of the study and providing a signed written informed consent~* Consent the use of facial images for marketing purposes and educational material~* Subject with moderate to very severe (Grade 2 to 4) on the GJS~* Subject is willing to abstain from any other facial, submental, and/or neck aesthetic procedure(s) or implant~* Female of childbearing potential with a negative urine pregnancy test before treatment~Exclusion Criteria:~* Subjects presenting with known/previous allergy or hypersensitivity to hyaluronic acid (HA) filler, lidocaine or other amide-type local anesthetics~* Subjects presenting with known/previous allergy or hypersensitivity to streptococcal proteins~* Subject with bleeding disorders or taking thrombolytics or anticoagulants~* Prior surgical procedure in the treatment area~* History of other facial treatment/procedure in the previous 6 months HA in or near the intended treatment site~* Presence of any disease or lesions near or on the area to be treated~* Presence of any condition, in the opinion of the Treating Investigator, makes the subject unable to complete the study per protocol~* Women who are pregnant or breast feeding, or women of childbearing potential who are not practicing adequate contraception or planning to become pregnant during the study period~* Study site personnel, close relatives of the study site personnel, employees, or close relatives of employees at the Sponsor Company~* Participation in any other interventional clinical study within 30 days before treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Initial Restylane Lyft Lidocaine injection and one optional touch-up treatment at 1 month after treatment
- No-treatment control group (Type: NO_INTERVENTION): Optional treatment will be administered at 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed invasive bladder cancer (T2-4a, N0, M0)~  * Adenocarcinoma~ * Transitional cell carcinoma~ * Squamous cell carcinoma~* Localized muscle invasion by surgery or imaging~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* WHO 0-2~Life expectancy:~* Not specified~Hematopoietic:~* WBC greater than 4,000/mm\^3~* Platelet count greater than 100,000/mm\^3~Hepatic:~* Bilirubin less than 1.5 times upper limit of normal (ULN)~* ALT or AST less than 1.5 times ULN~Renal:~* Glomerular filtration rate greater than 25 mL/min~Other:~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective contraception~* No inflammatory bowel disease~* No other prior malignancy within the past 2 years except adequately treated basal cell skin cancer or carcinoma in situ of the cervix~* No other prior malignancy or uncontrolled systemic disease that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy to the pelvis~Surgery:~* See Disease Characteristics~* No bilateral hip replacements~Other:~* No concurrent metronidazole during fluorouracil administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Persistence of IPV Immunity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~We will be including Nepali infants who fulfil the following criteria:~* Born after 30 April 2016~* Healthy infant or mild illness~* Age groups within one of the following age groups: 7-12 months or \>24 months.~* Receipt of one dose of IPV at 3- 6 months of age (if age \>24months) or zero doses (if age within 7-12 months). IPV receipt must be validated through immunization card or registry book.~* Parents that consent for participation in the full length of the study.~* Parents those are able to understand and comply with planned study procedures.~Exclusion Criteria:~* Parents and infants who are unable to participate in the full length of the study.~* A diagnosis or suspicion of immunodeficiency disorder either in the infant or in an immediate family member.~* A diagnosis or suspicion of bleeding disorder that would contraindicate parenteral administration of IPV or collection of blood by venipuncture.~* Acute infection or illness at the time of enrollment that would require infant's admission to a hospital.~* Evidence of a chronic medical condition identified by a study medical officer during physical exam.~* Known allergy/sensitivity or reaction to polio vaccines.~Discontinuation Criteria~* Withdrawal of consent for participation for any reason.~* Request by parents of participant to terminate all study procedures.~* Identification of immunodeficiency disorder, bleeding disorder or another medical condition for which continued participation, in the opinion of the principal investigator, would pose a risk to the participant to continue in the study.~* Receipt of immunosuppressive medications.~* Receipt of any polio (OPV or IPV) vaccine outside of study after enrollment (as per parent's report).~* Allergic reaction to a dose of polio vaccine.~* Unable to collect or obtain blood at enrollment.~* Premature termination of the study.~* Temporary discontinuation of study activities may occur if there is a mOPV2 campaign.

- Gender: ALL
- Minimum Age: 7 Months
- Maximum Age: 36 Months
- Healthy Volunteers: f

Study Arms:
- Study Arm A (Type: ACTIVE_COMPARATOR): Children {Age \> 24 months and who received a single dose Inactivated Polio Vaccine (IPV) at the time of routine immunization} in this arm will receive an IPV (0.5ml) intramuscularly at the time of enrolment in the trial
- Study arm B (Type: ACTIVE_COMPARATOR): Children {Age 7-12 months and have not received any IPV till date of enrolment} in this arm will receive an Inactivated Polio Vaccine, IPV (0.5 ml) intramuscularly at the time of enrolment in the trial and a repeat dose of IPV (0.5 ml) after 1 month

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetic Study of Different Hormone Therapies in Recent Menopause Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* last menstrual period between 6 months and 3 years before the beginning of the study plus FSH levels higher than 35 IU/L;~* age between 42 and 58 years;~* no use of any medication known to interfere with hormonal, glucose, or lipoprotein levels in the past 3 months;~* no use of steroidal or no steroidal anti-inflammatory drugs in the last 15 days.~Exclusion criteria:~* patients with diabetes,~* previous hysterectomy,~* endometrial thickness \>0.5cm,~* history of cancer,~* thromboembolism, or~* established cardiovascular disease

- Gender: FEMALE
- Minimum Age: 42 Years
- Maximum Age: 58 Years
- Healthy Volunteers: t

Study Arms:
- Non-oral hormone therapy (Type: ACTIVE_COMPARATOR): 3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
- oral homone therapy (Type: ACTIVE_COMPARATOR): estradiol 1mg and drospirenone 2 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Calcium Electroporation for Treatment of Cutaneous Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years.~* Histological confirmed cutaneous metastases of any histology.~* At least 1. cutaneous metastases between 0,5 to 3cm, available to electroporation.~* Patient should have been offered standard treatment.~* At least 2 weeks since chemotherapy or radiotherapy.~* Performance status \>2 (ECOG).~* Life expectancy \>3 months.~* platelet count \> 50 mia/l.~* International Normalized Ratio (INR) \<1,2.~* Men and women of reproductive age must use effective contraception during the study.~* Patient should be able to understand participants information.~* Signed, informed consent.~Exclusion Criteria:~* Previously treatment with bleomycin \> 200.000 Units/m2.~* Allergy to bleomycin.~* Clinically significant coagulopathy.~* Pregnancy or lactation.~* Participation in other clinical trial involving experimental drugs or participation in a clinical trial within 4 weeks before study treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Calcium electroporation (Type: EXPERIMENTAL): The metastases will be treated with intratumoral injection of calcium chlorid followed by electrotransfer.~It is a once-only treatment. Calcium chlorid concentration: 9mg/ml. Total dose: 0,5ml/cm3 tumor volume.
- Electrochemotherapy with bleomycin (Type: ACTIVE_COMPARATOR): The metastases will be treated with intratumoral injection of bleomycin followed by electrotransfer.~It is a once only treatment. bleomycin concentration: 1000 IU/ml. Total dose: o,5 ml/cm3 tumor volume.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Females aged greater than or equal to 20 years and less than 75 years at the time of informed consent.~* Histologically or cytologically confirmed with breast cancer~* Score 3+ by immunohistochemistry (IHC) or HER2 positive by Fluorescence in Situ Hybridization (FISH) method~* Subjects who meet any of the following criteria:~  * Evidence of recurrence during adjuvant chemotherapy with trastuzumab and taxane~ * Evidence of recurrence within 6 months after adjuvant chemotherapy with trastuzumab and taxane~ * Experienced prior chemotherapy including trastuzumab and taxane for advanced or recurrent breast cancer~* Adequate organ function~* Eastern Cooperative Oncology Group (ECOG)-Performance Status (PS) is 0 or 1~* Subjects who have submitted written informed consent for study entry~Exclusion Criteria~* Subjects with known brain metastasis accompanied by clinical symptoms or requiring active treatment~* Subjects with severe active infection requiring active treatment~* Subjects with large pleural effusions, ascites, or pericardial effusions requiring drainage.~* Hypersensitivity to trastuzumab, halicondrin B or halicondrin B chemical derivatives~* Known positive for human immunodeficiency virus (HIV) test or positive for hepatitis B surface (HBs antigen) or hepatitis C (HCV) by serum test.~* Subjects who are pregnant (positive B-hCG test) or breastfeeding~* Subjects judged to be ineligible for this study by the principal investigator or sub-investigator.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Present with chronic plaque psoriasis based on an investigator confirmed diagnosis of chronic psoriasis vulgaris for at least 6 months prior to baseline and meet the following criteria:~  * plaque psoriasis involving ≥10% body surface area (BSA) and absolute PASI score ≥12 in affected skin at screening and baseline~ * sPGA score of ≥3 at screening and baseline~* Candidate for biologic treatment for psoriasis.~Exclusion Criteria:~* Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product or could interfere with the interpretation of data.~* Breastfeeding or nursing (lactating) women.~* Have had serious, opportunistic, or chronic/recurring infection within 6 months prior to screening.~* Have received live vaccine(s) (included attenuated live vaccines) within 1 month of screening or intend to during the study.~* Have any other skin conditions (excluding psoriasis) that would affect interpretation of the results.~* Have received systemic nonbiologic psoriasis therapy or phototherapy within 28 days prior to baseline.~* Have received topical psoriasis treatment within 14 days prior to baseline.~* Have received anti-tumor necrosis factor (TNF) biologics, or anti-interleukin (IL)-17 targeting biologics within 8 weeks prior to baseline.~* Have previous exposure to any biologic therapy targeting IL-23 (including ustekinumab), either licensed or investigational (previous briakinumab use is permitted).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 30 mg Mirikizumab (Type: EXPERIMENTAL): 30 mg Mirikizumab administered subcutaneously (SC) every 8 weeks (Q8W).
- 100 mg Mirikizumab (Type: EXPERIMENTAL): 100 mg Mirikizumab administered SC Q8W.
- 300 mg Mirikizumab (Type: EXPERIMENTAL): 300 mg Mirikizumab administered SC Q8W.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC Q8W.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 to 65 years old~2. Asymptomatic hyperuricemia (sUA \> 6.0 mg/dL)~3. Body mass index between 18 and 35 kg/m2 inclusive and weight at least 50 kg and no more than 150 kg~4. Females must be non-pregnant, as well as post-menopausal or willing to use an acceptable method of contraception during the study.~Exclusion Criteria:~1. History of any clinically significant disease or disorder putting the patient at risk during the study, or influencing study results or ability to participate in the study~2. eGFR\* \< 45 mL/minute/1.73 m2 at Screening.~3. Type 2 diabetes mellitus with HbA1c \>8%.~4. History of diabetic ketoacidosis, hyperosmolar non-ketotic coma, gout, or alcohol or drug abuse.~5. Ongoing treatment with an SGLT2-inhibitor, a URAT1-inhibitor, and/or a xanthine oxidase inhibitor.~6. Positive test for hepatitis B, hepatitis C or HIV.~7. Use of any medications in the 2 weeks preceding first administration of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: EXPERIMENTAL): Randomized patients will receive orally once daily fixed dose of the following drugs:~verinurad + febuxostat + dapagliflozin;
- Treatment B (Type: EXPERIMENTAL): Randomized patients will receive orally once daily fixed dose of the following drugs:~verinurad + febuxostat + dapagliflozin matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative the Effect of Metformin and Acupuncture on Weight Loss and Insulin Sensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Who had been diagnosed with type 2 diabetes mellitus and has using Metformin monotherapy as well to control their diabetes during the period of this study as previously (500 mg one/two/three times per day)~* All patients were overweight according to BMI ≥25~Exclusion Criteria:~* Individuals with nephritic syndrome (urine protein over 3.5 g/day), edema or renal failure (serum creatinine over 115 µmol/L)~* Individuals who had been diagnosed with heart failure (NYHA Fc III-IV) or who had been a pacemaker implanted~* Individuals with abnormal liver dysfunction (GOT and glutamate-pyruvate transaminase (GPT) levels twofold above the normal range) or a diagnosis of liver cirrhosis~* Individuals with a high HbA1C level (HbA1C above 9 %)~* Pregnant women~* Individuals who were receiving insulin therapy already~* Individuals who receive other therapy or had any change at dosage during the period of therapy~* Individuals who were suffering from endocrine abnormalities such as Thyroid disease, polycystic ovary syndrome (PCOS), etc~* Individuals who were receiving weight loss medicine, anti depressant agents' or hormonal medicines during the last 3 months and the period of study~* Individuals who were suffering from a homeostasis disorder or other systemic disease~* Individuals who did not comply(signed informed consent) with the treatment during the study period

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- metformin & acupuncture (Type: EXPERIMENTAL): Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and acupuncture treatment including electro body acupuncture and Auricular acupuncture for 30 minutes, 10 times, every other day, for 3 weeks.
- metformin & placebo (Type: PLACEBO_COMPARATOR): Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and placebo acupuncture treatment, needling not in right acupoints and EA machine was switched off during 30 minutes of therapeutic time. For ear acupuncture was just used sticky layers without seeds. All placebo treatment used for 30 minutes, 10 times, every other day, for 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* idiopathic RLS with the presence of all four clinical manifestations of RLS~* RLS symptoms occur predominantly in the evening~* RLS history at least 6 months~* IRLS =\> 15 at the beginning and the end of placebo run-in~* Have =\>15 nights with RLS symptoms in the month prior to screening~Exclusion Criteria:~* Any secondary RLS~* Current augmentation due to RLS treatment~* Placebo responders identified during the placebo run-in

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PBO/PGB 300 mg (Type: EXPERIMENTAL): None
- PBO/PPX 0.25 mg (Type: ACTIVE_COMPARATOR): None
- PBO/PPX 0.5 mg (Type: ACTIVE_COMPARATOR): None
- PGB 300 mg (Type: EXPERIMENTAL): None
- PPX 0.25 mg (Type: ACTIVE_COMPARATOR): None
- PPX 0.5 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At least one claim for tofacitinib between 01 January 2014 and 31 January 2017 (the identification period).~* Presence of The International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9 CM) code for RA (in any position) during the one-year pre-index period or on the index date. ICD-9 = 714.0x-714.4x \& 714.81 or ICD10 = M05.\* \& M06.0\*-M06.3\* or M06.8\*-M06.9\*.~* At least 18 years old as of the index date.~Exclusion Criteria:~* Patients with claims for other conditions for which biologics are used during the one-year pre-index period or on the index date: ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis, or ulcerative colitis will be excluded from the study.~* Patients with evidence of the index medication during the one-year pre-index period will be removed from the analysis. Patients will be allowed to have been treated with other biologics approved for RA (Tumor-Necrosis Factor-alpha inhibitors (TNFi) \[adalimumab (Humira), etanercept (Enbrel), certolizumab pegol (Cimzia), golimumab (Simponi), infliximab (Remicade)\] and non-TNFi's with alternative mechanisms of action \[abatacept (Orencia), and rituximab (Rituxan), anakinra (Kineret), tocilizumab (Actemra)\]) during the one-year pre-index period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Truven Health MarketScan Research Database (Type: None): Compare treatment patterns including dosing, concomitant medication use, adherence, persistence, and switching among tofacitinb+MTX patients who withdraw MTX vs. persist with MTX or experience interrupted MTX

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete